Xyphos Biosciences collaborates on CAR-T cells for cancer treatment

18 October 2018
2019_biotech_test_vial_discovery_big

The Parker Institute for Cancer Immunotherapy and Xyphos Biosciences today announced a collaboration to create universal CAR-T therapies to treat multiple cancer types using the company's 'convertibleCAR' platform.

Xyphos was created last November as a spin-out from AvidBiotics, a privately held US biotechnology company.

Using this type of cell therapy, researchers endeavor to program a patient's own immune cells to attack tumor cells with greater specificity, and potentially lower toxicity, when directed to tumor antigens with separate targeting antibodies. Unlike the first generation of approved cell therapies, this technology aims to allow more controlled antigen recognition for greater responsiveness to the tumor environment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology